$ cat ./records/gates-foundation-provides-emergency-funding-for-north-kivu-ebola--2018.txt
Gates Foundation Provides Emergency Funding for North Kivu Ebola Outbreak in DRC
[RECORD.TXT] · cat --full
Within nine days of the North Kivu outbreak being confirmed in the Democratic Republic of Congo on 1 August 2018, the Gates Foundation provided WHO with $2 million in fast, flexible funding to accelerate the response. The North Kivu outbreak was complicated by active armed conflict and the worst security environment any Ebola response had ever faced. It became the second-largest Ebola epidemic on record, killing more than 2,000 people. Gates funding supported emergency operations including deployment of the rVSV-ZEBOV vaccine under an expanded access protocol.
Source: https://www.gatesfoundation.org/Ideas/Articles/Global-partners-respond-to-new-Ebola-outbreak
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Invests $275 Million in Ginkgo Bioworks Synthetic Biology Platform
Next →
Gates Foundation Commits $10 Million to MOSIP Open-Source Digital Identity Platform
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.